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ABSTRACT – 244 Words  
Background: Age related declines in walking performance may be partly attributable to skeletal 
muscle mitochondrial dysfunction as mitochondria produce over 90% of ATP needed for 
movement and the capacity for oxidative phosphorylation decreases with age.  
Methods: Participants were from two studies: an ancillary to the Lifestyle Interventions and 
Independence for Elders (LIFE) Study (n = 33), which recruited lower functioning participants 
(Short Physical Performance Battery [SPPB], 7.8 ± 1.2), and the Study of Energy and Aging-
Pilot (SEA, n = 29), which enrolled higher functioning (SPPB, 10.8 ± 1.4). Physical activity was 
measured objectively using the Actigraph accelerometer (LIFE) and SenseWear Pro armband 
(SEA).  Phosphocreatine recovery following muscle contraction of the quadriceps was measured 
using 31P magnetic resonance spectroscopy and ATPmax (mM ATP/s) was calculated. Walking 
performance was defined as time (s) to walk 400m at a usual-pace. The cross-sectional 
association between mitochondrial function and walking performance was assessed using 
multivariable linear regression. 
Results: Participants were 77.6 ± 5.3 years, 64.2% female and 67.2% white. ATPmax was 
similar in LIFE vs. SEA (0.52 ± 0.14 vs. 0.55 ± 0.14, p = 0.31), despite different function and 
activity levels (1.6 ± 2.2 vs.77.4 ± 73.3 min of moderate activity/day, p<0.01). Higher ATPmax 
was related to faster walk-time in SEA (r2 = 0.19, p = 0.02,); but not the LIFE (r2 <0.01, p = 
0.74) cohort.  
Conclusions: Mitochondrial function was associated with walking performance in higher 
functioning, active older adults, but not lower functioning, sedentary older adults. 
Key Words: Mitochondrial Function, Mobility, Aging, Muscle, Physical Performance; Walking 
Performance 
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INTRODUCTION 
 Walking performance decreases significantly with age, but with considerable individual 
variation (1). The underlying causes of age-related slowing are of great interest as slower gait is 
an independent risk factor for institutionalization (2) and mortality (3). The role of skeletal 
muscle in slowing walking performance is still unclear, as sarcopenia only modestly predicts 
mobility maintenance (or loss) in older adults (4). Further, maximum aerobic capacity (VO2peak) 
decreases with age independent of lean mass and physical activity levels (5). VO2peak is partly 
dependent on the ability of skeletal muscle mitochondria to produce adenosine triphosphate 
(ATP) and mitochondria produce over 90% of ATP needed for movement (6). The capacity for 
mitochondrial oxidative phosphorylation is lower in aged compared to younger skeletal muscle, 
as both mitochondrial function and content are reduced (7-8). However, this age associated 
decrease in mitochondrial content and function may also be due in part to reduced physical 
activity and not completely attributable to aging per se (9). Thus, lower mitochondrial function 
may play a role in the age-related slowing of gait speed. 
In fact, worse skeletal muscle mitochondrial function in older adults has been linked with 
higher fatigability (10), lower physical function (11) and slower gait speed (12). For example, 
Coen et al. showed that higher mitochondrial function was significantly associated with faster 
gait speed in higher functioning older adults (13). However, the relationship between 
mitochondrial function and walking performance has not been examined in older adults with 
both high and low levels of physical function.  The purpose of this research was to examine the 
cross-sectional relationship between mitochondrial energetics, measured by 31P magnetic 
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resonance spectroscopy (MRS), and walking performance in older adults with a wide range of 
functional capacity.  
 
METHODS 
Participants 
 Participants were from two studies, employing identical measures of mobility and 
mitochondrial capacity for oxidative phosphorylation. The higher functioning cohort was from 
the Study of Energy in Aging-Pilot (SEA) (10,13) and lower functioning participants were from 
an ancillary study to the Lifestyle Interventions and Independence for Elders (LIFE) Study (14).  
 SEA participants were community-dwelling (n = 37) men and women aged 70–89 years 
from the Pittsburgh, PA area and inclusion and exclusion criteria have been described in detail 
elsewhere (10,13). Briefly, inclusion criteria included body mass index 20–32kg/m2, ability to 
walk without an assistive device and free of basic activities of daily living disability. Exclusion 
criteria included history of hip fracture, heart attack, angioplasty, or heart surgery within the past 
3 months, cerebral hemorrhage within the past 6 months, stroke within the past 12 months, or 
symptomatic cardiovascular or pulmonary disease. Participants were assessed at the magnetic 
resonance imaging (MRI) center for 31P MRS scan eligibility for ability to lie in a supine position 
for 1-hour, no MR unsafe metal or other implants, bilateral joint replacements, and tattoos. The 
final analytical sample from SEA included 29 participants with complete MRS and 400m walk 
data.  
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 The LIFE Study was a multi-center randomized controlled trial designed to test the 
effectiveness of physical activity compared with health education on preventing mobility 
disability (14-15). Briefly, LIFE included sedentary adults aged 70–89, at high risk for mobility 
disability (Short Physical Performance Battery [SPPB, 0-12] score of ≤9) (16) but able to walk 
400 meters in <15 minutes. LIFE study recruitment began in March of 2010 and ended in 
December of 2011 for the full study. In May 2011, LIFE participants from the Pittsburgh field 
center were screened, and if eligible, invited to take part in an ancillary study visit prior to 
starting their intervention program. The ancillary visit included a 31P MRS scan, which had 
identical MR eligibility criteria to SEA. There were 91 LIFE participants randomized during this 
time and of these: 17 (18.7%) refused, 35 (38.5%) were ineligible (28 due to MR unsafe implants 
or bilateral knee/hip replacements) and 39 (42.9%) were eligible to participate in the MR 
ancillary study. Of the 39 eligible participants, 33 had useable MRS data, yielding a final LIFE 
analytic sample of 33. Thus, the final analytic sample included 29 SEA and 33 LIFE participants 
(total n=62). 
 Both LIFE and SEA study protocols were approved by the University of Pittsburgh 
Institutional Review Board. All participants provided written informed consent. 
Clinic Examination and Measurements 
 Participants completed clinic visits at the Health Studies Research Center at the 
University of Pittsburgh. Body height (cm) was measured using a wall-mounted stadiometer and 
body weight (kg) with a standard certified, calibrated scale, and used to calculate BMI (kg/(m2). 
Participants completed demographic and self-reported health questionnaires. Questions were 
phrased in a similar manner between studies with one exception: history of arthritis. In SEA, the 
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question asked about any history of arthritis, whereas LIFE asked about a doctor’s visit in the 
past 6-months for arthritis or rheumatism. Diabetes was defined as either self-reported diagnosis, 
use of diabetic hypoglycemic medication or fasting blood glucose ≥126 mg/dL. 
 Lower extremity function was assessed using the SPPB, a widely used performance 
measure scored on a 0-12 point scale. The test includes 3 parts: a 4m walk; 5 timed, repeated 
chair stands; and a balance battery each worth 0-4 points (16). Seven-day free-living physical 
activity was measured in both studies; LIFE used the Actigraph™ accelerometer (model GT3X, 
ActiGraph, LLC), while SEA employed the SenseWear™ Pro armband (BodyMedia, Pittsburgh, 
PA). NHANES cut-points (17) were used to categorize Actigraph counts, while the Sensewear’s 
proprietary algorithm was used to calculate minutes per day spent in moderate and above 
(≥3METs) intensity activities.  
 400-Meter Walk 
 Walk protocols for both studies were nearly identical (13-14). The only difference was 
that LIFE permitted use of a single pronged cane. In both studies the test was conducted on a 
level ground 20-meter course. Participants were instructed to walk at their usual pace, without 
overexertion for 10 laps (20m up and back). Following the walk, participants from both studies 
were asked “Is anything bothering you?” and reported symptoms were recorded. Discomfort 
following the walk was defined as responding yes to this question. One SEA participant of the 
original 37 was excluded from analyses due to not completing the 400m walk.  
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Determination of ATPmax by 31P MRS 
 MRS protocols were identical and both studies utilized the same MR magnet, technician 
and MRS analyst. Phosphocreatine (PCr) recovery after exercise (ATPmax) was used to quantify 
mitochondrial capacity for oxidative phosphorylation. 31P MRS has been validated by animal and 
human studies showing that ATPmax varies in direct proportion to oxidative enzyme activity of 
healthy muscle (18) and mitochondrial content in human muscle (7). ATPmax has good 
reproducibility illustrated by previously published Bland Altman analysis from SEA (19).  
 The exercise protocol was performed in an MRI magnet (3T TIM Trio, Siemens’ Medical 
System) (10,13). Participants laid supine with the right knee (unless contraindicated) elevated at 
~30º. Straps were placed over the legs and a 2.5” surface RF coil tuned to 31P was placed over 
the quadriceps. Participants performed repeated voluntary, rapid, maximal isometric contractions 
(kicking) for two bouts (30s and 36s) followed by a 6-minute rest. The protocol was designed to 
deplete PCr by 33-66% without inducing acidosis (pH <6.8). A monoexponential fit of [PCr] 
recovery yields the recovery constant (k) for use in calculating ATPmax:  
ATPmax = [PCr]rest•kPCr. 
Previous analyses of human vastus lateralis muscle biopsies revealed that ATP content accounted 
for the range of PCr/ATP levels among participants aged 65-80 years (7).  In contrast, PCr was 
stable (as was total creatine) and averaged 27mM.  Thus, we used 27mM for [PCr]rest (10,13). 
Finally, we determined pH from the chemical shift of the Pi peak relative to the PCr peak (20).  
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Statistical Analyses 
 The final analytic sample included 29 SEA and 33 LIFE participants with complete 
ATPmax and 400m data (total n=62). Baseline characteristics, means and standard deviations for 
continuous variables and frequencies and percents for categorical variables, were generated for 
each study. To test for between study differences, Wilcoxon rank-sum, chi-squared and Fischer’s 
exact tests were used where appropriate.  
 To determine the relationship between ATPmax and 400m walk time (s) multivariable 
linear regression was used. We present results for each group separately. Bivariate and 
multivariable models adjusted for age, sex, race, study and BMI were generated. The beta 
coefficients represent the difference in 400m walk time (in seconds) per 1 SD higher ATPmax 
(0.14 mM atp/s). Since it is has been shown that those with type 2 diabetes have impaired 
mitochondrial function(21), we also examined the effect of diabetes on the relationship between 
ATPmax and 400m walk time. Physical activity was considered last because it is a known 
determinant of muitochondrial function, as we have previously shown(13,22). All analyses were 
performed with SAS version 9.3. 
 
RESULTS 
Baseline Comparison of SEA and LIFE Study Participants 
 LIFE compared with SEA participants were significantly more overweight, less active, 
had lower SPPB scores, and slower 400m walk times (Table 1). Of note, only one SEA 
participant had an SPPB score <9, an inclusion criteria for LIFE. LIFE also contained a 
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significantly larger proportion of females and African Americans as well as a higher prevalence 
of diabetes and fewer reporting consuming 6 or more drinks per (Table 1). Despite significantly 
lower physical function and activity levels, LIFE had similar ATPmax compared with SEA (0.55 
± 0.14 vs. 0.52 ± 0.14mM ATP/s, p = 0.31).  
Table 1. Characteristics by Study and in Combination 
 SEA (n = 29) 
Mean (SD) or N (%) 
LIFE (n = 33) 
Mean (SD) or N (%) 
P-value for 
between study 
difference 
Age, yrs 78.6 (5.0) 76.6 (5.5) 0.14 
Sex , female 13 (44.8) 25 (75.8) 0.01 
Race, white 27 (93.1) 16 (48.5) <0.01 
BMI, kg/m2 26.0 (2.7) 30.8 (5.4) <0.01 
Smoker, current or former 10 (34.5) 9 (27.3) 0.54 
Alcohol, 6+ drinks/week 8 (27.6) 2 (6.1) 0.04 
Diabetes 1 (3.5) 9 (27.3) 0.01 
Myocardial infarction 3 (10.3) 1 (3.0) 0.33 
Chronic obstructive pulmonary 
disease 
1 (3.5) 3 (9.1) 0.62 
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Arthritis 9 (31.0) 6 (18.2) 0.24 
Moderate and above activity, 
min/day 
77.4 (73.3) 1.6 (2.2) <0.01 
SPPB, 0-12 10.8 (1.4) 7.8 (1.2) <0.01 
400m walk time, s 343.8 (65.5) 466.9 (110.1) <0.01 
Discomfort at end of 400m walk, yes 5 (17.2) 12 (36.4) 0.09 
ATPmax,  mM/s 0.52 (0.14) 0.55 (0.14) 0.31 
 
 In LIFE, 12 (36.4%) participants reported discomfort at the end of the walk compared 
with 5 (17.2%) from SEA (Table 1). More specifically, in LIFE, 3 participants reported back 
pain, 3 reported hip pain, 2 reported knee pain, 2 reported light headedness, 1 reported tiredness 
and foot pain, while 1 requested their straight cane due to general discomfort. In SEA, the 5 
participants who reported discomfort reported the following symptoms: shortness of breath and 
back pain, knee and calf pain, back pain, hip and calf pain, and foot pain.  
 Relationship between ATPmax and 400m Walk Time 
 Higher levels of ATPmax were significantly related to faster 400m walk time in SEA (ß 
= -29.3, p = 0.02), with ATPmax explaining 19% of the variance in walk time (Table 2, Figure 
1). However, no association was observed in LIFE (ß = 6.2, p = 0.74, Table 2, Figure 1). After 
adjustment for age, sex, race and BMI, the relationship between ATPmax and 400m walk time in 
the SEA was attenuated slightly (ß = -24.8, p = 0.08). Adding diabetes to the fully adjusted 
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models had no effect on the relationship between ATPmax and walk time (SEA: p = 0.95; LIFE: 
p = 0.52 for diabetes parameter) and there was no interaction between ATPmax and diabetes on 
walking time in either cohort (SEA: p > 0.99; LIFE: p = 0.15). Physical activity was uniformly 
low in LIFE and not associated with ATPmax (r = -0.06, p = 0.75), while it was in SEA (r = 
0.48, p <0.01), as we have previously shown(13,22).  
   
Table 2. Association between ATPmax and Time to Walk 400 meters by Study and in 
Combination 
Model 
Beta, s§ 
(per 0.14 mM/ATP/s) 
SE 
p-
value 
SEA (n = 29) – Unadjusted -29.3 11.6 0.02 
SEA – Adjusted*  -24.8 13.3 0.08 
LIFE (n = 33) - Unadjusted  6.2 19.5 0.75 
LIFE – Adjusted* 26.0 16.0 0.11 
SE: standard error 
*adjusted for age, race, sex and BMI 
§beta coefficients represent the difference in 400m walk time (in seconds) per 1 SD higher 
ATPmax (0.14 mM atp/s).  
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Caption for Figure 1. 
ATPmax is defined as phosphocreatine recovery in the quadriceps following an acute bout of 
exercise measured by 31P magnetic resonance spectroscopy. Unadjusted p-values and bivariate r2 
values for the relationship between ATPmax and 400m walk time were as follows: A.) r2 = 0.19, 
p = 0.02 for SEA and B.) r2 <0.01, p = 0.75 for LIFE. 
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DISCUSSION 
 High ATPmax was associated with faster time to walk 400m in higher functioning, active 
SEA participants, but not lower functioning, sedentary LIFE participants. This lack of an 
association is contrary to hypotheses generated from our previous work (13) as well as several 
other studies of older adults (11-12,23). Namely, higher mitochondrial function measured by 31P 
MRS was related to faster time to complete a get-up-and-go-test in French, lower functioning 
hospitalized (n=49, aged 86.1 ± 5.3 years) and higher functioning community-dwelling older 
adults (n=28, aged 74.5 ± 6.2 years) (12). Similarly, a muscle biopsy study in relatively younger 
(aged 62.0 ± 11.8) peripheral artery disease patients showed that higher mitochondrial function 
was related to longer walking time during a VO2 max test (23). Importantly, both of the 
previously mentioned studies measured mitochondrial function in the gastrocnemius muscle 
(12,23), whereas the current study used the quadriceps. The conflicting results could be 
attributable to studying different muscle groups, as previous cross-sectional work suggests aging 
may affect locomotory muscles differently (24). However, the vastus lateralis (VL)  muscle, the 
muscle of interest in the current study, may be more susceptible to age and physical activity 
related changes compared to the tibialis anterior muscle (24). Therefore, in theory the VL muscle 
would have been more closely associated with age related decreases in walking performance. 
Further, a study from Joseph et al. showed that participants with lower mitochondrial respiration 
rates and markers of biogenesis in permeabilized muscle fibers from the VL are also significantly 
more likely to have lower SPPB scores (11). Although both are locomotory muscles of the lower 
leg, perhaps mitochondrial function in the gastrocnemius and tibialis anterior muscles undergo 
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heterogeneous age-related changes possibly due to gait biomechanics. This issue requires further 
investigation in studies examining the relationship between walking performance and 
mitochondrial function in different muscle groups from the same individual. Further, 
longitudinal studies of different muscle groups are needed to truly understand the effects of age 
and physical activity on mitochondrial function.  
Another key finding was that ATPmax levels were nearly identical between SEA and 
LIFE even though the LIFE participants were much less physically active and lower functioning. 
This conflicts with two studies showing that sedentary older adults have impaired mitochondrial 
function compared with active (25) and a second finding  that lower functioning older adults 
possess worse mitochondrial bioenergetics compared with higher functioning as measured by the 
SPPB (11). These conflicting results may in part be explained by the different measures of 
mitochondrial function, as the two abovementioned studies used biopsy measures. However, 
ATPmax reflects in-vitro measures of mitochondrial function(13); perhaps ATPmax does not 
correlate as well with biopsy measures in lower function individuals. Future methodological 
work should investigate these associations in low functioning participants. 
The inconsistencies concerning the relationship between ATPmax and walking 
performance could be attributable to our walking performance measure (400m walk); however, 
lower functioning individuals walk closer to their maximal performance during a usual paced 
400m walk compared with higher functioning (26). Therefore, since ATPmax is highly related to 
VO2 peak (13), a stronger relationship would  have been expected in the lower functioning LIFE 
participants. Unless the LIFE participants had other impairments limiting walking performance, 
unrelated to oxidative capacity of the quadriceps, such as pain or joint stiffness. Indeed, although 
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the difference did not reach statistical significant, over twice the proportion of LIFE participants 
reported discomfort, mainly due to pain, during the walk compared with SEA (36% vs. 17%).    
 There are several possible explanations for why ATPmax was unrelated to 400m walk 
time in lower functioning participants. First, there may be differences in muscle mass that could 
affect walking time independent of ATPmax; however LIFE was lacking a measure of muscle 
mass. The, the higher prevalence of discomfort and pain experience by LIFE participants during 
the walk may have caused them to slow down for reasons unrelated to mitochondrial function. 
Joint impairments (27), arthritis (28), knee (29) and back pain (30) are associated with slower 
walking speed or physical disability in older adults. Secondly, the LIFE Study was lacking a 
measure of mitochondrial efficiency (P/O), which is related to exercise efficiency in older adults 
(31). Finally, since discomfort and pain may evoke alterations to normal gait (32), it is plausible 
that those with both higher levels of ATPmax and slower walk times were biomechanically 
inefficient. Thus, these participants may be producing more energy (ATP) to walk at the same 
speed (or more slowly) than a biomechanically efficient individual. Indeed, higher energy cost of 
walking (VO2 normalized to gait speed) is related to worse biomechanical gait parameters (33-
34) and impaired mobility (34-36). This may cause a less biomechanically efficient individual to 
have a higher ATPmax than their activity level or walking speed would suggest, which may also 
partially explain the phenomenon of similar ATPmax levels observed in SEA compared with 
LIFE. However, we cannot rule out the mediating role of other factors related to VO2 peak such 
as cardiopulmonary function. Further investigations are needed, particularly in lower functioning 
older adults, to further understand the interrelationships between ATPmax, gait biomechanics, 
energy cost of walking and walking performance. 
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 Strengths of this study include a larger sample size compared with previous work 
examining the relationship between skeletal muscle mitochondrial energetics and walking 
performance in older adults and including a diverse population in terms of sex, race, function and 
physical activity levels. Mitochondrial function was measured directly and in vivo using 31P 
MRS. Performance measures, as opposed to self-report, were used to quantify physical function 
and walking speed. Limitations include participants being from two separate studies; however, 
the study sites, primary outcome and predictor were identical. Muscle biopsies were not obtained 
in the LIFE cohort, so mitochondrial efficiency and other parameters could not be determined. 
The study was cross-sectional, thus no causal inferences can be made. Despite being the largest 
study to have examined these relationships to date, the sample size was still relatively small, 
which limited our ability to stratify by possible mediating/confounding factors, particularly those 
that differed across the study populations, or test for interactions.  
 In conclusion, our study provides important and novel insights into the role of skeletal 
muscle mitochondrial capacity for oxidative phosphorylation in walking performance in older 
adults. Specifically, ATPmax (functional oxidative capacity of the quadriceps) was unrelated to 
walking times in lower functioning, sedentary participants and those with a wide range of 
function. However, higher mitochondrial function was related to faster walking times in higher 
functioning, active participants. This suggests that lower mitochondrial function may be a marker 
of early functional decline in higher functioning older adults. Further, mitochondrial function 
does not appear to be a limiting factor in lower functioning participants, who may slow for other 
reasons such as pain while ambulating. Larger studies examining other aspects mitochondrial 
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energetics, energy cost and physical performance in older adults with wide age (e.g. aged 50-85) 
and physical function ranges are needed to further investigate these relationships. 
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